Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda = $265,000 (17 doses per year)

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Apr 13, 2023 12:39pm

144 Views

Post# 35393275

RE:Keytruda = $265,000 (17 doses per year)

Hi

I may be wrong but there is also the maint protocol for the last one so more likely to be 16-20 doses total.

Nadofaragene = $313,000 (4 doses for first year; up to 16 doses over 4 years)
Oportuzumab = $310,000 (36 doses in first year)
Keytruda = $265,000 (17 doses per year)
Gemcitabine + Docetaxel = $172,000 (6 doses total) - then monthly x 10 to 24 months depending on response.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks